| Name | Lumateperone tosylate |
|---|---|
| Synonyms |
ITI 007 tosylate
ITI 007 ITI-722; ITI722; ITI 722; ITI-007; ITI007; ITI 007; LUMATERONE, CAPLYTA Lumaterone PTSA salt lumateperone (Tosylate) ITI 722 tosylate lumaterone Tosylate, 10 mM in DMSO Lumefantrine tosylate Lumiperidone p-toluenesulfonate lumaterone (Tosylate) ITI007 tosylate Lumaterone Impurity 48 UNII:JIE88N006O 1-(4-Fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-1-butanone 4-methylbenzenesulfonate (1:1) Lumaterone, Caplyta ITI-007;ITI 007;ITI007;LUMATERONE;1187-9 ITI-007 tosylate lumaterone (Tosylate) ISO 9001:2015 REACH ITI722 tosylate Dopamine Rector,ITI007,schizophrenia,lumaterone Tosylate,Inhibitor,inhibit,dopamine D1 rector,5-HT2A,5-hydroxytryptamine Rector,presynaptic D2 rector,5-HT Rector,Lumaterone,ITI 007,postsynaptic D2 rector,Serotonin Rector Lumaterone P-toluenesulfonate Salt ITI-722 tosylate (6bR,10aS)-8-[4-(4-Fluorophenyl)-4-oxobutyl]-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-ium 4-methylbenzenesulfonate Lumaterone toluenesulfonic acid (PTSA salt) Lumaterone Tosylate Salt 1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-, 4-methylbenzenesulfonate (1:1) Lumaterone(ITI-007) 1-(4-Fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,7,10,10a-hexahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(9H)-yl)butan-1-one 4-methylbenzenesulfonate |
| Description | Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). IC50 value: 0.54 nM (Ki, for 5-HT2A receptor )Target: 5-HT2A receptorLumateperone also possesses affinity for the D1 receptor (Ki = 52 nM) and weak affinity for the α1A- and α1B-adrenergic receptors (Ki = 173 nM at α1) and D4 receptor. Lumateperone does not significantly bind to the 5-HT2B, 5-HT2C, H1, or mACh receptors. Lumateperone shows a 60-fold difference in its affinities for the 5-HT2A and D2 receptors, which is far greater than that of most or all existing atypical antipsychotics, such as risperidone (12-fold), olanzapine (12.4-fold), and aripiprazole (0.18-fold).[1]in vivo: It is thought that this property may improve the effectiveness and reduce the side effect profile of Lumateperone relative to currently-available antipsychotics, a hypothesis which is supported by the observation of minimal catalepsy in mice treated with Lumateperone.[1] |
|---|---|
| Related Catalog | |
| References |
[1]. Lumateperone |
| Molecular Formula | C31H36FN3O4S |
|---|---|
| Molecular Weight | 565.699 |
| Exact Mass | 565.241028 |
| Storage condition | 2-8℃ |